Mary Wilson
Well-known member
Available online 7 April 2021
https://doi.org/10.1016/S2666-5247(21)00068-9
SoniaJangra[SUP]a[/SUP][SUP]c[/SUP]ChengjinYe[SUP]f[/SUP]RaveenRathnasinghe[SUP]a[/SUP][SUP]c[/SUP][SUP]d[/SUP]DanielStadlbauer[SUP]a[/SUP]
It is concerning that emerging variants of SARS-CoV-2 can evade neutralising antibodies induced by previous infection or vaccination through mutations in the spike protein, including the receptor-binding domain (RBD). The asparagine (N) to tyrosine (Y) substitution at position 501 (N501Y), present in variants of concern belonging to the B.1.1.7, B.1.351, and P.1 lineages, does not seem to affect in-vitro neutralisation of human convalescent or post-vaccination sera. However, additional substitutions, such as E484K present in B.1.351 and P.1 lineages, might allow evasion from neutralising antibodies.1, 2, 3, 4 ...
https://www.sciencedirect.com/science/article/pii/S2666524721000689
https://doi.org/10.1016/S2666-5247(21)00068-9
SoniaJangra[SUP]a[/SUP][SUP]c[/SUP]ChengjinYe[SUP]f[/SUP]RaveenRathnasinghe[SUP]a[/SUP][SUP]c[/SUP][SUP]d[/SUP]DanielStadlbauer[SUP]a[/SUP]
It is concerning that emerging variants of SARS-CoV-2 can evade neutralising antibodies induced by previous infection or vaccination through mutations in the spike protein, including the receptor-binding domain (RBD). The asparagine (N) to tyrosine (Y) substitution at position 501 (N501Y), present in variants of concern belonging to the B.1.1.7, B.1.351, and P.1 lineages, does not seem to affect in-vitro neutralisation of human convalescent or post-vaccination sera. However, additional substitutions, such as E484K present in B.1.351 and P.1 lineages, might allow evasion from neutralising antibodies.1, 2, 3, 4 ...
https://www.sciencedirect.com/science/article/pii/S2666524721000689